{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:44:32Z","timestamp":1792226672084,"version":"4.4.0"},"reference-count":106,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lodz","award":["503\/1-151-02\/503-11-001"],"award-info":[{"award-number":["503\/1-151-02\/503-11-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Minimal Change Disease (MCD) is a predominant cause of idiopathic nephrotic syndrome in the pediatric population, yet presents significant clinical challenges due to its frequent relapses and steroid resistance. Despite its relatively benign histological appearance, MCD is characterized by severe proteinuria, hypoalbuminemia, and edema, which may affect patient outcomes. Current treatment strategies primarily rely on corticosteroids, which are effective in inducing remission but are associated with high relapse rates, steroid resistance, and numerous long-term side effects, underscoring the need for more targeted and effective therapeutic approaches. This narrative review synthesizes current knowledge on the pathophysiological mechanisms underlying MCD, focusing on the following three critical areas: podocyte dysfunction, immune dysregulation, and genetic susceptibility. Podocyte dysfunction, particularly involving alterations in nephrin, plays a central role in the breakdown of the glomerular filtration barrier, leading to the characteristic proteinuria observed in MCD. Immune dysregulation, including the presence of autoantibodies against nephrin and other podocyte components, exacerbates podocyte injury and contributes to disease progression, suggesting an autoimmune component to the disease. Genetic factors, particularly mutations in the NPHS1 and NPHS2 genes, have been identified as significant contributors to disease susceptibility, influencing the variability in treatment response and overall disease severity. Understanding these mechanisms is crucial for developing targeted therapies that address the underlying causes of MCD rather than merely managing its symptoms. This review highlights the need for further research into these pathophysiological processes to pave the way for more personalized and effective treatment strategies, ultimately improving patient outcomes and reducing reliance on corticosteroids.<\/jats:p>","DOI":"10.3390\/ijms252212174","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T06:23:16Z","timestamp":1731478996000},"page":"12174","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility"],"prefix":"10.3390","volume":"25","author":[{"given":"Maja","family":"Roman","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hypertension, Transplantation and Internal Medicine, Central University Hospital, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-5440","authenticated-orcid":false,"given":"Micha\u0142","family":"Nowicki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension, Transplantation and Internal Medicine, Central University Hospital, Medical University of Lodz, Pomorska 251, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Avner, E.D., Harmon, W.E., Niaudet, P., Yoshikawa, N., Emma, F., and Goldstein, S.L. (2016). Pediatric Nephrology, Springer. [7th ed.].","DOI":"10.1007\/978-3-662-43596-0"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"937623","DOI":"10.1155\/2012\/937623","article-title":"An Overview of Molecular Mechanism of Nephrotic Syndrome","volume":"2012","author":"Machado","year":"2012","journal-title":"Int. J. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00467-016-3379-4","article-title":"Pathogenesis of proteinuria in idiopathic minimal change disease: Molecular mechanisms","volume":"31","author":"Clapp","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ajpath.2011.12.023","article-title":"The Gne M712T Mouse as a Model for Human Glomerulopathy","volume":"180","author":"Kakani","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1681\/ASN.2012070734","article-title":"The Treatment of Minimal Change Disease in Adults","volume":"24","author":"Hogan","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003495-199142010-00003","article-title":"Management of Nephrotic Syndrome in Childhood","volume":"42","author":"Melvin","year":"1991","journal-title":"Drugs"},{"key":"ref_7","unstructured":"DynaMed [Internet] (2024, October 28). Dynamed.com. Available online: https:\/\/www.dynamed.com\/condition\/minimal-change-disease#GUID-7696237B-A946-4335-B43E-095830792AEB."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000481633","article-title":"A Review of Podocyte Biology","volume":"47","author":"Garg","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1681\/ASN.2021060794","article-title":"Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology","volume":"33","author":"Watts","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ndt\/18.1.70","article-title":"Altered ultrastructural distribution of nephrin in minimal change nephrotic syndrome","volume":"18","author":"Wernerson","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/01913123.2023.2292590","article-title":"Punctate IgG staining particles localize in the budding ballooning clusters of reactive foot processes in minimal change disease","volume":"48","author":"Zhang","year":"2023","journal-title":"Ultrastruct. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2249.2005.02838.x","article-title":"Possible role of autoantibodies against nephrin in an experimental model of chronic graft-versus-host disease","volume":"141","author":"Nagahama","year":"2005","journal-title":"Clin. Exp. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Webend\u00f6rfer, M., Reinhard, L., Stahl, R.A.K., Wiech, T., Mittr\u00fccker, H.-W., Harendza, S., and Hoxha, E. (2021). Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.586012"},{"key":"ref_14","unstructured":"Mansur, A. (2023, February 08). Minimal-Change Disease Treatment & Management: Approach Considerations, Consultations, Diet and Activity. eMedicine [Internet]. 30 March 2023. Available online: https:\/\/emedicine.medscape.com\/article\/243348-treatment?form=fpf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00467-003-1346-3","article-title":"Expression of nephrin in acquired forms of nephrotic syndrome in childhood","volume":"19","author":"McDonald","year":"2004","journal-title":"Pediatr. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/j.ekir.2021.03.475","article-title":"POS-449 Adult onset minimal change disease: Clinical characteristics, treatment and prognosis","volume":"6","author":"Asma","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2215\/CJN.06180519","article-title":"Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease","volume":"15","author":"Lawrence","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ndt\/gfw235","article-title":"Clinical trials in minimal change disease","volume":"32","author":"Ravani","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Giannou, P., Gakiopoulou, H., Stambolliu, E., Petras, D., Chalkia, A., Kapota, A., Palamaris, K., Hadziyannis, E., Thomas, K., and Alexakou, Z. (2024). Urine Nephrin and Podocalyxin Reflecting Podocyte Damage and Severity of Kidney Disease in Various Glomerular Diseases\u2014A Cross-Sectional Study. J. Clin. Med., 13.","DOI":"10.20944\/preprints202405.0073.v1"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hayward, S., Parmesar, K., Welsh, G.I., Suderman, M., and Saleem, M.A. (2023). Epigenetic Mechanisms and Nephrotic Syndrome: A Systematic Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020514"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/ckj\/sft063","article-title":"Minimal-change disease in adolescents and adults: Epidemiology and therapeutic response","volume":"6","author":"Keskar","year":"2013","journal-title":"Clin. Kidney J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1093\/ndt\/gfr128","article-title":"Messenger RNA expression of B7-1 and NPHS1 in urinary sediment could be useful to differentiate between minimal-change disease and focal segmental glomerulosclerosis in adult patients","volume":"26","author":"Espinal","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1681\/ASN.V132388","article-title":"Novel Mutations in NPHS2 Detected in Both Familial and Sporadic Steroid-Resistant Nephrotic Syndrome","volume":"13","author":"Karle","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1051\/medsci\/20082410853","article-title":"Pathog\u00e9nie du syndrome n\u00e9phrotique \u00e0 lesions glom\u00e9rulaires minimes","volume":"24","author":"Audard","year":"2008","journal-title":"M\u00e9decine\/Sciences"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Machuca, E., Esquivel, E.L., and Antignac, C. (2009). Idiopathic Nephrotic Syndrome: Genetic Aspects, Springer.","DOI":"10.1007\/978-3-540-76341-3_27"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2215\/CJN.07200712","article-title":"Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome","volume":"8","author":"McCarthy","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hsiao, C.C., Tu, K.H., Hsieh, C.Y., Lee, C.C., Chang, C.H., Fan, P.C., Tian, P.C., and Fang, J.T. (2018). Immunoglobulin E and G Levels in Predicting Minimal Change Disease before Renal Biopsy. BioMed Res. Int., 2018.","DOI":"10.1155\/2018\/3480309"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0002-9440(10)64128-4","article-title":"Nephrin Redistribution on Podocytes Is a Potential Mechanism for Proteinuria in Patients with Primary Acquired Nephrotic Syndrome","volume":"158","author":"Doublier","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"147032031668122","DOI":"10.1177\/1470320316681223","article-title":"Possible role for glomerular-derived angiotensinogen in nephrotic syndrome","volume":"17","author":"Yamazaki","year":"2016","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.V122289","article-title":"Expression of Nephrin in Pediatric Kidney Diseases","volume":"12","author":"Patrakka","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-020-01854-3","article-title":"New insight into podocyte slit diaphragm, a therapeutic target of proteinuria","volume":"24","author":"Kawachi","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kanazawa, N., Iyoda, M., Suzuki, T., Tachibana, S., Nagashima, R., and Honda, H. (2023). Exploring the significance of interleukin-33\/ST2 axis in minimal change disease. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-45678-z"},{"key":"ref_34","unstructured":"(2024, November 02). Minimal Change Disease [Internet]. www.kidneypathology.com. Available online: https:\/\/www.kidneypathology.com\/English_version\/Minimal_change_disease.html."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Purohit, S., Piani, F., Ordo\u00f1ez, F.A., de Lucas-Collantes, C., Bauer, C., and Cara-Fuentes, G. (2021). Molecular Mechanisms of Proteinuria in Minimal Change Disease. Front. Med., 8.","DOI":"10.3389\/fmed.2021.761600"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Jiang, H., Shen, Z., Zhuang, J., Lu, C., Qu, Y., Xu, C., Yang, S., and Tian, X. (2024). Understanding the podocyte immune responses in proteinuric kidney diseases: From pathogenesis to therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1335936"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/labinvest.2008.125","article-title":"Expression of galectin-1, a new component of slit diaphragm, is altered in minimal change nephrotic syndrome","volume":"89","author":"Shimizu","year":"2008","journal-title":"Lab. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1681\/ASN.2006070710","article-title":"Overexpression of Interleukin-13 Induces Minimal-Change\u2013Like Nephropathy in Rats","volume":"18","author":"Lai","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ndt\/gfh648","article-title":"Interleukin-13 genetic polymorphisms in Singapore Chinese children correlate with long-term outcome of minimal-change disease","volume":"20","author":"Wei","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.kint.2022.10.023","article-title":"Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis","volume":"103","author":"Mariani","year":"2023","journal-title":"Kidney Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2017.08.017","article-title":"NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation","volume":"68","author":"Song","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"sfad289","DOI":"10.1093\/ckj\/sfad289","article-title":"Early growth response 1 as a podocyte injury marker in human glomerular diseases","volume":"17","author":"Okabe","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_43","unstructured":"(2024, October 04). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06405100?cond=Minimal%20Change%20Disease&limit=100&page=1&rank=4."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Feng, Y., Li, M., Wang, Y., Yang, M., Shi, G., Yin, D., Xuan, Z., and Xu, F. (2022). Activation of TRPC6 by AngII Induces Podocyte Injury and Participates in Proteinuria of Nephrotic Syndrome. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.915153"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Chehade, H., Cachat, F., Girardin, E., Rotman, S., Correia, A.J., Fellmann, F., and Bonny, O. (2013). Two new families with hereditary minimal change disease. BMC Nephrol., 14.","DOI":"10.1186\/1471-2369-14-65"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Gembillo, G., Siligato, R., and Santoro, D. (2023). Personalized Medicine in Kidney Disease. J. Pers. Med., 13.","DOI":"10.3390\/jpm13101501"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ma, S., Qiu, Y., and Zhang, C. (2024). Cytoskeleton Rearrangement in Podocytopathies: An Update. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010647"},{"key":"ref_48","first-page":"839","article-title":"Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis","volume":"27","author":"Siligato","year":"2018","journal-title":"Mol. Membr. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kandasamy, Y., Smith, R., Lumbers, E.R., and Rudd, D. (2014). Nephrin\u2014A biomarker of early glomerular injury. Biomark. Res., 2.","DOI":"10.1186\/2050-7771-2-21"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/ped.14005","article-title":"CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood","volume":"61","author":"Eroglu","year":"2019","journal-title":"Pediatr. Int."},{"key":"ref_51","first-page":"1363","article-title":"CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: Diagnostic and pathogenic significance","volume":"29","author":"Wei","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/CS20190961","article-title":"IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease","volume":"134","author":"Low","year":"2020","journal-title":"Clin. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"SzSzeto, C.C., So, H., Poon, P.Y.K., Luk, C.C.W., Ng, J.K.C., Fung, W.W.S., Chan, G.C.K., Chow, K.M., Lai, F.M.M., and Tam, L.S. (2023). Urinary Long Non-Coding RNA Levels as Biomarkers of Lupus Nephritis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411813"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000538825","article-title":"Identification of Plasma hsa_circ_0001230 and hsa_circ_0023879 as Potential Novel Biomarkers for Focal Segmental Glomerulosclerosis and circRNA-miRNA-mRNA network analysis","volume":"49","author":"Ran","year":"2024","journal-title":"Kidney Blood Press. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00467-021-05352-w","article-title":"The potential of RNA-based therapy for kidney diseases","volume":"38","author":"Bondue","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"George, S., Rafi, M., Aldarmaki, M., ElSiddig, M., Al Nuaimi, M., and Amiri, K.M.A. (2022). tRNA derived small RNAs\u2014Small players with big roles. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.997780"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lou, W., Ding, B., and Fu, P. (2020). Pseudogene-Derived lncRNAs and Their miRNA Sponging Mechanism in Human Cancer. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00085"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.kint.2024.06.027","article-title":"Pseudogene GSTM3P1 derived long non-coding RNA promotes ischemic acute kidney injury by target directed microRNA degradation of kidney-protective mir-668","volume":"106","author":"Wei","year":"2024","journal-title":"Kidney Int."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Bharati, J., Kumar, M., Kumar, N., Malhotra, A., and Singhal, P.C. (2023). MicroRNA193a: An Emerging Mediator of Glomerular Diseases. Biomolecules, 13.","DOI":"10.3390\/biom13121743"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6499668","DOI":"10.1155\/2022\/6499668","article-title":"The Role of Cytokines in Nephrotic Syndrome","volume":"2022","author":"Ahmadian","year":"2022","journal-title":"Mediat. Inflamm."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zhang, N., Zhao, P., Shrestha, A., Zhang, L., Qu, Z., Liu, M., Zhang, S., and Jiang, Y. (2014). A Higher Frequency of CD4+CXCR5+T Follicular Helper Cells in Adult Patients with Minimal Change Disease. BioMed Res. Int., 2014.","DOI":"10.1155\/2014\/836157"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1177\/1535370216651937","article-title":"Original Research: Potential of urinary nephrin as a biomarker reflecting podocyte dysfunction in various kidney disease models","volume":"241","author":"Wada","year":"2016","journal-title":"Exp. Biol. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.humpath.2010.05.028","article-title":"Immunohistochemical evaluation of podocalyxin expression in glomerulopathies associated with nephrotic syndrome","volume":"42","author":"Kavoura","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chebotareva, N.A., Vinogradov, A., McDonnell, V., Zakharova, N., Indeykina, M.I., Moiseev, S., Nikolaev, E.N., and Kononikhin, A.S. (2021). Urinary Protein and Peptide Markers in Chronic Kidney Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212123"},{"key":"ref_65","unstructured":"(2024, October 04). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00981838?cond=Minimal%20Change%20Disease%20%5C(MCD%5C)&limit=100&rank=9."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ekir.2023.02.1070","article-title":"Rituximab as Initial Therapy in Adult Patients with Minimal Change Disease","volume":"8","author":"Guan","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nrneph.2016.147","article-title":"Minimal change disease and idiopathic FSGS: Manifestations of the same disease","volume":"12","author":"Maas","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000535010","article-title":"Efficacy of Rituximab for Minimal Change Disease and Focal Segmental Glomerulosclerosis with Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome in Adults: A Chinese Multicenter Retrospective Study","volume":"55","author":"Lan","year":"2024","journal-title":"Am. J. Nephrol."},{"key":"ref_69","first-page":"e22313","article-title":"Rituximab for Steroid-Dependent Minimal Change Disease in Adults: Is It Time for a Change?","volume":"14","author":"Kannan","year":"2022","journal-title":"Cureus"},{"key":"ref_70","unstructured":"(2024, October 04). Clinicaltrials.gov. 2024, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06405100?cond=Minimal%20Change%20Disease%20%5C(MCD%5C)&limit=100&rank=2."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.krcp.2012.10.003","article-title":"The use of tacrolimus in the management of minimal change disease","volume":"31","author":"Chai","year":"2012","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s11255-022-03122-7","article-title":"Efficacy and safety of tacrolimus versus corticosteroid as initial monotherapy in adult-onset minimal change disease: A meta-analysis","volume":"54","author":"Lu","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"ref_73","unstructured":"(2024, October 04). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01092962?cond=Minimal%20Change%20Disease&limit=100&page=1&rank=87."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e10.1","DOI":"10.1053\/j.ajkd.2003.11.015","article-title":"Mycophenolate therapy in frequently relapsing minimal change disease that has failed cyclophosphamide therapy","volume":"43","author":"Pesavento","year":"2004","journal-title":"Am. J. Kidney Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfx035","article-title":"Efficacy of mycophenolate treatment in adults with steroid-dependent\/frequently relapsing idiopathic nephrotic syndrome","volume":"10","author":"Sandoval","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_76","unstructured":"(2024, October 04). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03210688?cond=Minimal%20Change%20Disease&limit=100&page=1&rank=8."},{"key":"ref_77","unstructured":"(2024, October 04). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01835639?cond=Minimal%20Change%20Disease&limit=100&page=1&rank=99."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal Change Disease","volume":"12","author":"Vivarelli","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_79","unstructured":"(2024, October 04). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04387448?cond=Minimal%20Change%20Disease&limit=100&page=1&rank=45."},{"key":"ref_80","unstructured":"(2024, October 04). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05441826?cond=Minimal%20Change%20Disease&limit=100&page=1&rank=11."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/ndt\/gfae025","article-title":"Management of adult patients with podocytopathies\u2014An update from the ERA Immunonephrology Working Group","volume":"39","author":"Mirioglu","year":"2024","journal-title":"Nephrol. Dial. Transplant.\/Nephrol. Dial. Transplant."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1053\/j.ajkd.2011.07.024","article-title":"New Insights Into Human Minimal Change Disease: Lessons From Animal Models","volume":"59","author":"Chugh","year":"2012","journal-title":"Am. J. Kidney Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"412","DOI":"10.12688\/f1000research.7300.1","article-title":"Cell biology and genetics of minimal change disease","volume":"5","author":"Saleem","year":"2016","journal-title":"F1000Research"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.ekir.2023.02.141","article-title":"WCN23-0353 Renal biopsy registry from a single centre in india: 20 years experience","volume":"8","author":"Veeramaneni","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Pereira, L.H., da Silva, C.A., Monteiro, M.L., Ara\u00fajo, L.S., Rocha, L.P., Reis, M.B., Ramalho, F.S., Corr\u00eaa, R.R., Silva, M.V., and Reis, M.A. (2019). Podocin and uPAR are good biomarkers in cases of Focal and segmental glomerulosclerosis in pediatric renal biopsies. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217569"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Eikrem, \u00d8., Lillefosse, B., Delaleu, N., Strauss, P., Osman, T., Vikse, B.E., Debiec, H., Ronco, P., Sekulic, M., and Koch, E. (2023). Network-Based Assessment of Minimal Change Disease Identifies Glomerular Response to IL-7 and IL-12 Pathways Activation as Innovative Treatment Target. Biomedicines, 11.","DOI":"10.3390\/biomedicines11010226"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.52225\/narra.v3i2.184","article-title":"Application of CRISPR-Cas9 genome editing technology in various fields: A review","volume":"3","author":"Ansori","year":"2023","journal-title":"Narra J."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Garc\u00eda, F., Mart\u00ednez-Pulleiro, R., Carrera, N., Allegue, C., and Garcia-Gonzalez, M.A. (2022). Genetic Kidney Diseases (GKDs) Modeling Using Genome Editing Technologies. Cells, 11.","DOI":"10.3390\/cells11091571"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2209392","DOI":"10.1080\/0886022X.2023.2209392","article-title":"Combination of the gut microbiota and clinical indicators as a potential index for differentiating idiopathic membranous nephropathy and minimal change disease","volume":"45","author":"Jiang","year":"2023","journal-title":"Renal Failure"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1111\/j.1523-1755.2004.00583.x","article-title":"Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS)","volume":"65","author":"Lahdenkari","year":"2004","journal-title":"Kidney Int."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat. Med."},{"key":"ref_92","unstructured":"Meyrier, A., and Radhakrishnan, J. (2024, October 04). UpToDate [Internet]. Uptodate.com. Available online: https:\/\/www.uptodate.com\/contents\/minimal-change-disease-treatment-in-adults\/print."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Nagai, K. (2023). Immunosuppressive Agent Options for Primary Nephrotic Syndrome: A Review of Network Meta-Analyses and Cost-Effectiveness Analysis. Medicina, 59.","DOI":"10.3390\/medicina59030601"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome","volume":"38","author":"Trautmann","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0272-6386(03)00652-8","article-title":"Polymorphisms of interleukin-4\u2014Related genes in Japanese children with minimal change nephrotic syndrome","volume":"42","author":"Kobayashi","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Hodson, E., Knight, J., Willis, N., and Craig, J. (2005). Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst. Rev., CD001533.","DOI":"10.1002\/14651858.CD001533.pub3"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"F46","DOI":"10.1152\/ajprenal.00184.2016","article-title":"The podocyte as a direct target for treatment of glomerular disease?","volume":"311","author":"Mallipattu","year":"2016","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.1365-2249.2001.01678.x","article-title":"T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation","volume":"126","author":"Chintalacharuvu","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"ref_99","first-page":"2867","article-title":"Changes of serum IL-6, IL-10 and TNF-\u03b1 levels in patients with systemic lupus erythematosus and their clinical value","volume":"13","author":"Jin","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Richter, P., Macovei, L.A., Mihai, I.R., Cardoneanu, A., Burlui, M.A., and Rezus, E. (2023). Cytokines in Systemic Lupus Erythematosus\u2014Focus on TNF-\u03b1 and IL-17. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914413"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"ii209","DOI":"10.1093\/ndt\/gfw365","article-title":"Clinicopathologic correlations of renal pathology in the adult population of Poland","volume":"32","author":"Bartczak","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1523-1755.2004.00833.x","article-title":"Clinicopathologic correlations of renal pathology in Spain","volume":"66","author":"Rivera","year":"2004","journal-title":"Kidney Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e15880","DOI":"10.1097\/MD.0000000000015880","article-title":"Clinicopathologic correlations of renal biopsy findings from northeast China","volume":"98","author":"Su","year":"2019","journal-title":"Medicine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/ckj\/sfaa247","article-title":"Activation of the acute inflammatory phase response in idiopathic nephrotic syndrome: Association with clinicopathological phenotypes and with response to corticosteroids","volume":"14","author":"Roca","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"109412","DOI":"10.1016\/j.intimp.2022.109412","article-title":"Cytokines network in primary membranous nephropathy","volume":"113","author":"Zhao","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_106","unstructured":"Rawla, P., and Limaiem, F. (2024, April 22). IgA Nephropathy [Internet], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538214\/."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/22\/12174\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:31:28Z","timestamp":1760113888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/22\/12174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":106,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ijms252212174"],"URL":"https:\/\/doi.org\/10.3390\/ijms252212174","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}